Guangdong New Southern Group Co., Ltd.

Founded in 1994, Guangdong New Southern Group Co., Ltd. is an international comprehensive investment group. The group focuses on the traditional Chinese medicine (TCM) industry, with core investments including Artemisinin Pharmaceutical, Denglao Herbal Tea, and Yanghe Medicine. Its investment areas also cover real estate, energy, hotels, finance, culture, and new retail. Since 2006, the group has leveraged the artemisinin-based antimalarial project as a starting point, implementing the "Rapid Malaria Elimination with Compound Artemisinin" project in countries such as Comoros, Togo, and Papua New Guinea, successfully saving millions of lives with its original compound artemisinin drugs, earning it the title of "China's business card" in international aid. In recent years, responding to the national "Belt and Road" development strategy, the group has built overseas parks as a support point to establish a platform for Chinese enterprises to go global. It now operates two overseas economic and trade cooperation zones: the Nigeria Guangdong Economic and Trade Cooperation Zone and the Kenya Pearl River Special Economic Zone, positioning itself as a pioneer and practitioner of the "Belt and Road" initiative. The group currently has over 2,000 employees and collaborates closely with research institutions such as Peking University and Guangzhou University of Chinese Medicine, housing a large number of highly educated and expert talents. The company has a well-established management system, a comprehensive training system, and a strong talent pool. Looking ahead, the group remains committed to the mission of public health, striving to inherit and promote Chinese medicine culture, and forging ahead toward becoming an internationally renowned large-scale investment group!